Correction to: Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
Following publication of the original article [1], the authors notified us of a few requested editions that were not implemented adequately during proofing. The publisher apologizes for the inconvenience caused to our authors and readers.
Main Authors: | Juan Carlos Villar, Víctor Mauricio Herrera, Juan Guillermo Pérez Carreño, Eliana Váquiro Herrera, Yeny Zulay Castellanos Domínguez, Skarlet Marcell Vásquez, Zulma Milena Cucunubá, Nilda Graciela Prado, Yolanda Hernández |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Trials |
Online Access: | http://link.springer.com/article/10.1186/s13063-019-3630-y |
Similar Items
-
Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
by: Juan Carlos Villar, et al.
Published: (2019-07-01) -
Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
by: Nidia Acosta, et al.
Published: (2020-12-01) -
Susceptibilidad in vitro a hexadecilfosfocolina (miltefosina), nifurtimox y benznidazole de cepas de Trypanosoma cruzi aisladas en Santander, Colombia
by: Patricia Escobar, et al.
Published: (2009-09-01) -
In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV
by: Susana Revollo, et al.
Published: (2019-10-01) -
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022-08-01)